Livagen vs Vilon
Comparison of Livagen (Low evidence) and Vilon (Low evidence).
Last updated: February 12, 2026
Livagen
Vilon
Overview
Livagen and Vilon are both studied in the peptide research space.
Livagen: A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression.
Vilon: A synthetic dipeptide (Lys-Glu) developed by Russian scientist Vladimir Khavinson as part of the peptide bioregulation framework.
Evidence Comparison
| Aspect | Livagen | Vilon |
|---|---|---|
| Evidence Level | Low | Low |
| Human Studies | 2 | 2 |
| Preclinical Studies | 8 | 10 |
| Total Sources | 12 | 15 |
Key Differences
| Aspect | Livagen | Vilon |
|---|---|---|
| Category | Other | Immune |
| Evidence Strength | Low | Low |
| Total Sources | 12 | 15 |
| Human Studies | 2 | 2 |
Summary
- Livagen: Low evidence with 12 total sources (2 human)
- Vilon: Low evidence with 15 total sources (2 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.